Clinical decision support algorithm based on machine learning to assess the clinical response to anti–programmed death-1 therapy in patients with non–small-cell lung cancer

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

(2020) Francesco Pantano et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma

(2020) Xuanwen Bao et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

A Machine Learning Approach for High-Dimensional Time-to-Event Prediction With Application to Immunogenicity of Biotherapies in the ABIRISK Cohort

(2020) Julianne Duhazé et al.   Frontiers in Immunology

Machine Learning–Based Model for Prediction of Outcomes in Acute Stroke

(2019) JoonNyung Heo et al.   STROKE

Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer

(2019) M Wiesweg et al.   ANNALS OF ONCOLOGY

Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer

(2018) Andrew J Rech et al.   CANCER RESEARCH

Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR -Mutant Patients

(2018) Marina Chiara Garassino et al.   Journal of Thoracic Oncology

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

(2018) Fabio Conforti et al.   LANCET ONCOLOGY

Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis

(2018) Bingjia Li et al.   OncoTargets and Therapy

Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer

(2018) TAKAYUKI SHIROYAMA et al.   ANTICANCER RESEARCH

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer

(2018) MARTIN SVATON et al.   ANTICANCER RESEARCH

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

(2017) Bingshan Liu et al.   Journal of Hematology & Oncology

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab

(2017) Tomoko Funazo et al.   Journal of Thoracic Oncology

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

(2017) Stefan Diem et al.   LUNG CANCER

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

(2017) Stephen J. Bagley et al.   LUNG CANCER

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Machine learning applications in cancer prognosis and prediction

(2015) Konstantina Kourou et al.   Computational and Structural Biotechnology Journal

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

What are artificial neural networks?

(2008) Anders Krogh   NATURE BIOTECHNOLOGY